Michael Wolff Jensen

General Counsel at ASCENDIS PHARMA A/S

Net worth: 291 909 $ as of 2024-03-30

53 year

92 connections

Health Technology

Utilities

Consumer Services

Active connections

Name	Gender	Age	Linked companies	Collaboration
Jan Mikkelsen	M	65	ASCENDIS PHARMA A/S VELOXIS PHARMACEUTICALS A/S Ascendis Pharma Endocrinology Division A/S Ascendis Pharma Endocrinology Division A/S Pharmaceuticals: MajorHealth Technology Ascendis Pharma Endocrinology Division A/S engages in pharmaceutical preparations. The company was founded on June 29, 2012 and is headquartered in Hellerup, Denmark. Ascendis Pharma Bone Diseases A/S Ascendis Pharma Growth Disorders AS VISEN Pharmaceuticals (Shanghai) Co., Ltd. VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	22 years
Lotte Sønderbjerg	F	62	ASCENDIS PHARMA A/S VELOXIS PHARMACEUTICALS A/S	21 years
An Bang Lu	M	58	VISEN Pharmaceuticals (Shanghai) Co., Ltd. VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	6 years
Albert Cha	M	51	ASCENDIS PHARMA A/S	10 years
Peter Rasmussen	M	55	ASCENDIS PHARMA A/S VELOXIS PHARMACEUTICALS A/S	12 years
Lisa Bright	F	56	ASCENDIS PHARMA A/S	7 years
Yi Bo Cao	M	42	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China. VISEN Pharmaceuticals (Shanghai) Co., Ltd. VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction.	3 years
Dan Dan Dong	M	40	VISEN Pharmaceuticals (Shanghai) Co., Ltd. VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	6 years
Kennett Sprogøe	M	46	ASCENDIS PHARMA A/S	17 years
Rasmus Errboe	M	45	ORSTED A/S	12 years
William Fairey	M	59	ASCENDIS PHARMA A/S	2 years
Scott Smith	M	50	ASCENDIS PHARMA A/S	8 years
Martine van Vugt	M	71	GENMAB A/S	23 years
Lars Holtug	M	66	ASCENDIS PHARMA A/S	6 years
Pierre Armand Morgon	M	61	EUROCINE VACCINES AB	11 years
Carl-Johan Dalsgaard	M	68	Vicore Pharma AB Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Vicore Pharma AB researches and develops pharmaceutical products. The company is headquartered in Gothenburg, Sweden.	-
Hong Ni	F	52	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	3 years
Peng Kuan Chan	M	61	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	3 years
Zheng Bin Yao	M	58	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	3 years
Siham Imani	F	47	ASCENDIS PHARMA A/S	2 years
Shan Fu	M	56	VISEN Pharmaceuticals (Shanghai) Co., Ltd. VISEN Pharmaceuticals (Shanghai) Co., Ltd. Pharmaceuticals: MajorHealth Technology VISEN Pharmaceuticals (Shanghai) Co., Ltd. is a Chinese pharmaceutical company that focuses on the development of products and technology for endocrine diseases. The company is based in Shanghai, China, and the CEO of the company is An Bang Lu. The company has developed a product called Long Pei, which is the first American FDA-approved growth hormone that can be released within a week to deliver growth hormone. VISEN Pharmaceuticals has also entered into a strategic cooperation agreement with Peking University Clinical Research Institute to carry out clinical research on thyroid dysfunction. VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	6 years
Heidi Hunter	F	66	VICORE PHARMA HOLDING AB	4 years
Jan Nils Sandström	M	86	EUROCINE VACCINES AB	12 years
Melinda Baker	F	-	ASCENDIS PHARMA A/S	-
Hans Jeppsson	M	-	Vicore Pharma AB Vicore Pharma AB Pharmaceuticals: MajorHealth Technology Vicore Pharma AB researches and develops pharmaceutical products. The company is headquartered in Gothenburg, Sweden.	-
Sze Ting Chan	F	42	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	-
Elin Rosendahl	F	-	VICORE PHARMA HOLDING AB	4 years
Birgitte Stephensen	F	63	GENMAB A/S	22 years
Tim Lee	M	-	ASCENDIS PHARMA A/S	-
Anni Lotte Kirstine Pedersen	F	-	Ascendis Pharma Endocrinology Division A/S Ascendis Pharma Endocrinology Division A/S Pharmaceuticals: MajorHealth Technology Ascendis Pharma Endocrinology Division A/S engages in pharmaceutical preparations. The company was founded on June 29, 2012 and is headquartered in Hellerup, Denmark.	12 years
Jessica Shull	M	-	VICORE PHARMA HOLDING AB	3 years
Stina Singel	M	50	ASCENDIS PHARMA A/S	4 years
Maha Katabi	M	50	Ascendis Pharma, Inc.	-
Jun Yang	M	52	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	4 years
Jun Chen	M	54	VISEN Pharmaceuticals VISEN Pharmaceuticals BiotechnologyHealth Technology VISEN Pharmaceuticals operates as a biopharmaceutical company. It focuses on developing therapies and patient-centric care on endocrine diseases. The firm operates a segment which is developing and commercializing paradigm-shifting endocrine therapies in Greater China. The company was founded on November 1, 2018 and is headquartered in Shanghai, China.	3 years
Flemming Steen Jensen	M	63	ASCENDIS PHARMA A/S	9 years

Connections Chart

Multi-company connection

Former connections

Name	Gender	Age	Linked companies	Collaboration
Rafaèle Elisabeth Tordjman	M	54	ASCENDIS PHARMA A/S	13 years
Thomas Soloway	M	56	ASCENDIS PHARMA A/S	5 years
Birgitte Volck	M	61	ASCENDIS PHARMA A/S	7 years
Michael Blair Widmer	M	76	GENMAB A/S	11 years
Benny Dalgaard Loft	M	59	ORSTED A/S	7 years
Anja Leschly	F	52	VELOXIS PHARMACEUTICALS A/S	-
Tom Vink	M	61	GENMAB A/S	-
Henrik Poulsen	M	57	ORSTED A/S	8 years
Martin Olin	M	55	ASCENDIS PHARMA A/S	4 years
Peter Schøtt Knudsen	M	51	VELOXIS PHARMACEUTICALS A/S	-
Michael Beckert	M	-	ASCENDIS PHARMA A/S VELOXIS PHARMACEUTICALS A/S	12 years
Carsten Krogsgaard Thomsen	M	67	ORSTED A/S	11 years
Bo Kruse	M	52	GENMAB A/S	8 years
Pia Gjellerup	F	65	ORSTED A/S	7 years
Jonathan Silverstein	M	57	ASCENDIS PHARMA A/S	-
James Healy	M	58	ASCENDIS PHARMA A/S	8 years
Thomas Dyrberg	M	69	VELOXIS PHARMACEUTICALS A/S	13 years
Kurt Anker Nielsen	M	78	VELOXIS PHARMACEUTICALS A/S	7 years
Karsten Havkrog Pedersen	M	74	GENMAB A/S	11 years
Thomas A. Larson	M	62	ASCENDIS PHARMA A/S	-
Kathrine Westermann	F	-	ORSTED A/S	-
Rasmus Nagel	M	-	ORSTED A/S	3 years
Rikke Glahn Ren	F	-	GENMAB A/S	-
Dana Pizzuti	M	69	ASCENDIS PHARMA A/S	2 years
Daniel Muthmann	M	-	ORSTED A/S	-
Jorgen Petersen	M	-	GENMAB A/S	-
Marie Olliver	M	-	EUROCINE VACCINES AB	-
Patrick van Berkel	M	55	GENMAB A/S	9 years
Christina Aabo	F	-	ORSTED A/S	10 years
Breian Knudsen	M	-	VELOXIS PHARMACEUTICALS A/S	9 years
Mark Bach	M	67	ASCENDIS PHARMA A/S	-
Rune Róin	M	-	ORSTED A/S	-
Tomas Lykke Nielsen	M	-	ORSTED A/S	-
Sigurd Okkels	M	-	ASCENDIS PHARMA A/S	4 years
Christian Skakkebæk	M	-	ORSTED A/S	10 years
Gérard Soula	M	78	VELOXIS PHARMACEUTICALS A/S	-
Grethe Nørskov Rasmussen	M	62	ASCENDIS PHARMA A/S	11 years
Jytte Koed Madsen	F	71	ORSTED A/S	-
Anders Eldrup	M	76	ORSTED A/S	11 years
Jean Deleage	M	83	VELOXIS PHARMACEUTICALS A/S	-
Lars Rebien Sørensen	M	69	ORSTED A/S	5 years
Martin Auster	M	49	ASCENDIS PHARMA A/S	2 years
Mark Brennan	M	61	ASCENDIS PHARMA A/S	-
Torben Nissen	M	53	ASCENDIS PHARMA A/S	3 years
Edwin de Graaf	M	-	ASCENDIS PHARMA A/S	-
Francesca DeMartino	F	-	VELOXIS PHARMACEUTICALS A/S	-
Jens Kampmann	M	86	ORSTED A/S	7 years
Thomas Dalsgaard	M	58	ORSTED A/S	3 years
Joseph Fred Yospe	M	66	GENMAB A/S	2 years
Paul W. H. I. Parren	M	60	GENMAB A/S	16 years
Lena Birgitta Degling Wikingsson	M	61	EUROCINE VACCINES AB	4 years
Jonathan Leff	M	66	ASCENDIS PHARMA A/S	3 years
Jesper Høiland	M	63	ASCENDIS PHARMA A/S	2 years
Neil Ringdahl	M	-	ASCENDIS PHARMA A/S	-
Karsten Anker Petersen	M	53	ORSTED A/S	-
Niels Svenstrup	M	54	ASCENDIS PHARMA A/S	2 years

Statistics

Country	Connections	% of total
Denmark	72	78.26%
China	11	11.96%
Sweden	9	9.78%
United States	1	1.09%

Age of Connections

Active

Past

Male

Female

Members of the board

Executives

Origin of connections